What the FDA labels say about taking them together
Anhydrous citric acid/magnesium oxide/sodium picosulfate and tetracycline
Anhydrous citric acid/magnesium oxide/sodium picosulfate's FDA label of April 15, 2026 names tetracycline in its drug interactions section; tetracycline's label does not name anhydrous citric acid/magnesium oxide/sodium picosulfate itself but warns about its class (anti-coagulants). The anhydrous citric acid/magnesium oxide/sodium picosulfate label: “Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with …”
Check it at the source: the anhydrous citric acid/magnesium oxide/sodium picosulfate FDA label on DailyMed (effective April 15, 2026); the tetracycline FDA label on DailyMed (effective March 18, 2025, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.).
What does the anhydrous citric acid/magnesium oxide/sodium picosulfate label say about tetracycline?
Anhydrous citric acid/magnesium oxide/sodium picosulfate label, drug interactionsAdminister tetracycline and fluoroquinolone antibiotics [see Drug Interactions (7.3) ], iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.
Source: FDA drug label (CLENPIQ), Ferring Pharmaceuticals Inc., effective April 15, 2026 (SPL set e95fff66-4ec0-4001-a727-33e66a5ec7d5), via openFDA; the full label on DailyMed
What does the tetracycline label say about anhydrous citric acid/magnesium oxide/sodium picosulfate?
Tetracycline's label does not name anhydrous citric acid/magnesium oxide/sodium picosulfate itself; it warns about its class (anti-coagulants):
Tetracycline label, drug interactionsBecause the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Source: FDA drug label (tetracycline hydrochloride), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective March 18, 2025 (SPL set eaa5b1bd-0927-46e4-b941-32fcc492d258), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Anhydrous citric acid/magnesium oxide/sodium picosulfate | Tetracycline | |
|---|---|---|
| Labeled for | n/a | Bacterial infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.518 per mL 175 mL solution | $0.247 per capsule 250 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once